bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
Laboratories around the world have paused regular work to pursue treatment for COVID-19. While there are still no evidence-based treatments available, scientists are evaluating a variety of options beyond supportive care.
The COVID-19 pandemic poses a threat to our antibiotic infrastructure, which is already compromised due to a lack of new therapies. That threat makes antimicrobial stewardship even more important.
Patients at the greatest risk for secondary infections, particularly infections that are resistant to first-line antibiotics, include people who are already vulnerable due to other conditions and diseases—like COVID-19. Because of that, antimicrobial resistance poses a significant additional threat, especially as healthcare systems become overburdened.
Hospitalizations with acute kidney injury (AKI) more than quadrupled in the US from 2000-2014 and clinicians are increasingly recognizing AKI as an in-hospital complication of sepsis, heart conditions, and surgery.
At this year’s World Anti-Microbial Resistance Congress, Dr. Tristan Timbrook delivered a...
WASH, which stands for water, sanitation, and hygiene, are basic...